Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Convocatoria de propuestas del programa H2020 (tema IMI2-2016-09-01): Abordar la carga clínica de infección por Clostridium difficile (CDI). Búsqueda de centros de investigación, pymes y socios académicos

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDUK20160601001
Publicado:
03/06/2016
Caducidad:
03/06/2017
Resumen:
Un grupo de un centro de investigación británico especializado en salud pública busca investigadores con el fin de presentar una propuesta a la convocatoria del programa H2020 dentro del tema IMI2-2016-09-01. El objetivo es abordar la carga clínica de infección por Clostridium difficile (CDI), incluyendo la evaluación de la carga, las prácticas actuales y la creación de una plataforma europea de investigación. El grupo de investigación busca centros de investigación, pymes y socios académicos con experiencia y competencias para participar en el proyecto. La fecha límite de la primera fase de la convocatoria es el 26 de julio de 2016 y el plazo para presentar expresiones de interés finaliza el 24 de junio.

Details

Tittle:
H2020 call for proposal under topic IMI2-2016-09-01, addressing the burden of clostridium difficile infection (CDI): Partners sought from research institutes, SMEs and academia
Summary:
A toxin group of a UK research organisation specialising in public health seeks research partners for topic IMI2-2016-09-01 proposal. The project focus is to address the clinical burden of clostridium difficile infection (CDI) including evaluation of the burden, current practices and set-up of a European research platform. Partners sought are research institutions, SMEs and academia with relevant active research/expertise or capabilities to support the project.
Description:
Infection with clostridium difficile, a gram-positive spore-forming anaerobe, is the most common cause of nosocomial diarrhoea in developed countries and leads to symptoms that range from self-limiting mild to moderate watery diarrhoea to severe fulminant diarrhoea, abdominal pain and pseudomembranous colitis. In some patients it may progress to toxic megacolon, colonic perforation and death. Over 500,000 new cases of C. difficile infection occur each year in the US and estimates suggest greater than 400,000 diagnosed CDI events occur annually in Europe, although the true incidence is likely to be much higher. Furthermore, the burden of CDI outside of the acute care hospital environment, particularly in nursing homes and long-term care facilities, is under-estimated. There is therefore a need to develop a robust assessment of the burden of CDI and current practices in Europe.

The scope of the project is to develop a detailed understanding of the epidemiology and clinical impact of CDI and more specifically to:

· align and understand the unmet public health needs relating to CDI;
· identify the direct and long term burden on healthcare systems;
· set up an EU research platform that will provide support for potential proof of concept studies of new prevention and treatment strategies.

The organisation seeking partners focuses on public health research and encourages discussions, advises government and supports action by local government, the National Health Service and other organisations. With significant experience in previous FP7, H2020 and other EU funding streams, they are actively engaged in applied research in microbiology and working across a range of aspects of microbial translational research. Key skills and expertise include protein chemistry, protein expression and purification, molecular biology, anaerobic microbiology, cellular assays and models, animal models for healthcare associated infections. Able to contribute significantly to work package 3 of the topic ´build a research network and platform´ they have an established a toolbox of reagents and techniques which could contribute to basic and translational research related to CDI. These include:

· highly purified C. difficile toxins
· polyclonal and monoclonal antitoxins
· recombinant toxin fragments and bacterial surface proteins
· quantitative toxin-neutralisation assays
· animal models for CDI

The organisation would be able to contribute to the project in the following ways:

· facilitating research in partner(s) labs through the provision of reagents and model systems.
· facilitating varied research at partner lab(s) e.g. pathogenesis research, diagnostics or translational research into interventions.
· provide reagents (e.g. toxins, antibodies) and\or model systems (in vitro or in vivo assays)

Alternatively to collaborate on the development of an oral vaccine as follows:
· collaborate on an orally delivered vaccine in which partner(s) have expertise in oral vaccine formulation\delivery or novel vectors
· provide candidate antigens (gene\protein), other reagents and\or model systems (in vitro or in vivo assays)

They are seeking partners from other research institutes, SMEs and academia and research activities carried out by interested organisations can be diverse as they in the early stages of forming consortia and would be open to negotiating the scope of the project to ensure that all consortium partners are represented.

The deadline for the stage 1 of the two-stage call is 26 July 2016 and the deadline for expressions of interest from interested institutions should be made no later than by 24 June 2016. The deadline for the second stage of the call is 10 January 2017 and the project is expected to start in Q3 2017.
Advantages and Innovations:
The project impact can be expected to result in the support of adequate public health intervention and practices. It will help in speeding up the development of alternative prevention and treatment approaches.

Key capabilities offered by the organisation relevant to the intended project include:

· optimisation of recombinant protein downstream processing and purification including optimisation of expression.
· development and qualification of in vitro assays (including cell-based assays)
· animal model development.
· production of highly purified bacterial protein toxins and other native proteins.

It is also envisaged that consortium will be formed alongside a group of highly experienced research institutions from the UK who represent national experts in:

· pathogenesis and structural studies on C. difficile toxins/surface proteins and on various virulence factors associated with gram-negative HCAIs (E. coli, Klebsiella pneumoniae).
· research into development of C. difficile immunotherapeutics.
· convalescent sera from ExPEC patients and epidemiological trends and characterisation of key HCAI-related bacterial strains
· clinical aspects of C. difficile immunotherapeutics.

Negotiations in this respect are on-going at this stage.
Stage of Development:
Proposal under development

Partner sought

Partner Sought:
Research institutions, academia, industrial partners and SMEs from EU and other eligible countries are sought. The research activities carried out by interested organisations can be diverse as the UK organisation is in the early stages of forming consortia and would be open to negotiating the scope of the project to ensure that all consortium partners are represented. Potential partners with relevant research expertise and capabilities in the following fields would be welcomed: · pathogenesis research, diagnostics or translational research into interventions. · oral vaccine formulation\delivery or novel vectors
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Other
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Dissemination

Programme-call

Evaluation Scheme:
The deadline for the stage 1 of the two-stage call is 26 July 2016. The deadline for the second stage of the call is 10 January 2017 and the project is expected to start in Q3 2017
Coordinator Required:
No
Deadline for Call:
26/07/2016
Project Duration:
0